Japan Dermatology Drugs Market Analysis Report 2022 to 2030

Japan Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Japan dermatology drugs market will reach a value of $2.5 Bn from $1.06 Bn in 2022, growing at a CAGR of 11.3% during 2022-2030. The market is primarily dominated by local players such as Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Shionogi & Co., Ltd. The market is driven by an ageing population, increasing awareness of skin diseases, and the launch of new and innovative drugs. The dermatology drug market in Japan is segmented by drug class, drug type, prescription mode, indication, route of administration, end user and distribution channel.

ID: IN10JPPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Dr. Vishwa Modhia

Buy Now

Japan Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Japan dermatology drugs market will reach a value of $2.5 Bn from $1.06 Bn in 2022, growing at a CAGR of 11.3% during 2022-30.

Japan is the third largest pharmaceutical market in the world, sizing at $95 Bn, and a critical export market for US pharmaceuticals. Eczema, also known as atopic dermatitis, is the most prevalent skin condition in Japan, affecting 10% of the population. Psoriasis, acne, and seborrheic dermatitis are next in prevalence. In Japan, there were approximately 3,046 general hospitals with dermatology departments as of October 2021. Japan has a large and aging population, which drives demand for healthcare services and products.

japan dermatology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

The share of dermatological pharmaceutical production in 2020 was 2.8%. Although Japan's population as a whole is declining, the country's retiree population is growing, which will increase the demand for medicine in the coming years.

The Japanese government has attempted to speed up approvals and be more accommodating with regard to the acceptance of data from foreign clinical trials in order to overcome the drug lag that historically caused registration to be 3-5 years behind the US and EU approvals.

Market Restraints

Japan has a strong pharmaceutical industry, with many large companies based in the country. This might refrain other companies from entering the market.

Competitive Landscape

Key Players

Takeda Pharmaceutical Company Limited (JPN)
Astellas Pharma (JPN)
Shionogi (JPN)
Eisai (JPN)
Janssen Pharmaceutical (JPN)
Kaken Pharmaceutical (JPN)
Derma pharm (JPN)
GlaxoSmithKline Pharmaceuticals Ltd.
Johnson & Johnson Limited
Novartis Japan Limited
Pfizer Limited

Notable Recent Deals

March 2022: Galderma, specializing in skin-related disorders. has been acquired by Taro Pharmaceuticals, a Sun Pharma US subsidiary, in the US, Japan, and Canada. Proactiv YK, a Japanese corporation, has agreed to let Taro Pharmaceutical Industries buy all of its outstanding capital stock.

December 2022: The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the manufacturing and marketing of Adtralza (tralokinumab), a subcutaneous injection, for adults with atopic dermatitis that has not adequately responded to standard treatments, according to LEO Pharma, a global leader in medical dermatology.

Healthcare Policies and Regulatory Landscape

Good Manufacturing Practice (GMP) for pharmaceuticals is known as Japanese GMP, or J-GMP, in Japan. Good Quality Practice (GQP), Good Vigilance Practice (GVP), Good Clinical Practice (GCP), and Good Post-Marketing Study Practice (GPSP) are additional pharmaceutical and drug quality standards that are specific to Japan.

The Pharmaceuticals and Medical Devices Agency (PMDA) office conducts the reviews necessary for the approval, re-examinations, and revaluations of dermatologic drugs in Japan and confirms clinical trial notifications and adverse drug reactions.

Reimbursement Scenario

The National Health Insurance (NHI) program of Japan eventually covers the cost of almost all medicines sold there. The Ministry of Health, Labour, and Welfare (MHLW) adopts reimbursement levels for medications based on recommendations made by the Central Social Insurance Medical Council (Chuikyo). The Japanese government offers universal health coverage, has been working to cut costs, and aspires to reduce the country's overall healthcare spending.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.